|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:dolutegravir
gptkb:lamivudine
|
|
gptkbp:approvalYear
|
2019-04-08
|
|
gptkbp:ATCCode
|
J05AR21
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:form
|
gptkb:tablet
fixed-dose combination tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dovato
|
|
gptkbp:indication
|
HIV-1 infection
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketingAuthorizationHolder
|
gptkb:ViiV_Healthcare
|
|
gptkbp:mechanismOfAction
|
integrase inhibitor and nucleoside reverse transcriptase inhibitor combination
|
|
gptkbp:notRecommendedFor
|
patients with known resistance to dolutegravir or lamivudine
patients with hepatitis B coinfection
|
|
gptkbp:onceDaily
|
true
|
|
gptkbp:pregnancyCategory
|
consult healthcare provider
|
|
gptkbp:prescriptionRequired
|
true
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
headache
insomnia
|
|
gptkbp:usedFor
|
adults with HIV-1 without resistance to integrase inhibitors or lamivudine
treatment-naive adults with HIV-1
|
|
gptkbp:bfsParent
|
gptkb:dolutegravir
|
|
gptkbp:bfsLayer
|
6
|